keyword
https://read.qxmd.com/read/38612819/therapeutic-advances-and-challenges-for-the-management-of-hpv-associated-oropharyngeal-cancer
#1
REVIEW
Isis de Araújo Ferreira Muniz, Megan Araujo, Jenna Bouassaly, Fatemeh Farshadi, Mai Atique, Khashayar Esfahani, Paulo Rogerio Ferreti Bonan, Michael Hier, Marco Mascarella, Alex Mlynarek, Moulay Alaoui-Jamali, Sabrina Daniela da Silva
The use of conventional chemotherapy in conjunction with targeted and immunotherapy drugs has emerged as an option to limit the severity of side effects in patients diagnosed with head and neck cancer (HNC), particularly oropharyngeal cancer (OPC). OPC prevalence has increased exponentially in the past 30 years due to the prevalence of human papillomavirus (HPV) infection. This study reports a comprehensive review of clinical trials registered in public databases and reported in the literature (PubMed/Medline, Scopus, and ISI web of science databases)...
April 3, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/36169285/a-mobile-thrombus-of-the-thoracic-aorta
#2
JOURNAL ARTICLE
Ammie Wolf, Simone Fajer, Menashi Haddad, Ali Shnaker, Mones Ajaj, Maysam Shehab
A mobile thrombus of the thoracic aorta is a rare entity, which might have serious clinical manifestations, including arterial emboli. Due to its low incidence, there is no consensus regarding the most adequate management of mobile thoracic aorta thrombus. The current case describes a patient with Polycythemia Vera and myeloproliferative neoplasm, who presented with mobile thrombus of the thoracic aorta, manifested by blue toe syndrome and asymptomatic splenic infarct. She was treated conservatively with anti-coagulation and Iloprost alongside the patient's permanent treatment of Aspirin, Hydrea and Atorvastatin...
September 28, 2022: Vascular and Endovascular Surgery
https://read.qxmd.com/read/33488839/bronchoalveolar-lavage-fluid-review-in-acute-promyelocytic-leukemia-differentiation-syndrome
#3
Robert P Seifert, Scott Gregory
The patient was a 62-year-old Caucasian man with blood smear and flow cytometry concerning for acute promyelocytic leukemia with FISH ultimately confirming PML-RARA translocation. He had a 30-year history of employment at a nuclear power plant. He presented with diffuse intravascular coagulation, hyperleukocytosis, and quickly developed acute respiratory distress syndrome. On day four of ATRA + Hydrea, a bronchoalveolar lavage was performed and was non-bloody. On microscopic fluid review, abnormal immature cells with bilobed nuclear contours were identified, similar in morphology to those seen on the diagnostic blood smear review, amidst background alveolar-type macrophages...
January 17, 2021: Journal of Hematopathology
https://read.qxmd.com/read/32634273/first-extensive-polyphenolic-profile-of-erodium-cicutarium-with-novel-insights-to-elemental-composition-and-antioxidant-activity
#4
JOURNAL ARTICLE
Vanja Ljoljić Bilić, Uroš Gašić, Dušanka Milojković-Opsenica, Ivan Nemet, Sanda Rončević, Ivan Kosalec, Jadranka Vuković Rodriguez
Erodium cicutarium is known for its total polyphenolic content, but this work reveals the first highly detailed profile of E. cicutarium , obtained with UHPLC-LTQ OrbiTrap MS 4 and UHPLC-DAD MS/MS techniques. A total of 85 phenolic compounds were identified and 17 constituents quantified. Overall, 25 new compounds were found, which have not yet been reported for the Erodium genera, or the family Geraniaceae. Along with methanolic extracts, the so far poorly investigated water extracts exhibited in vitro antioxidant activity according to all performed assays, including the ferric reducing/antioxidant power assay (FRAP), 2,2-diphenyl-1-picrylhydrazyl assay (DPPH), 2,2'-azinobis(3-ethylbenzthiazoline-6-sulphonic acid) assay (ABTS) and cupric ion reducing antioxidant capacity assay (CUPRAC)...
July 7, 2020: Chemistry & Biodiversity
https://read.qxmd.com/read/31414160/enzymatic-rhamnosylation-of-anticancer-drugs-by-an-%C3%AE-l-rhamnosidase-from-alternaria-sp-l1-for-cancer-targeting-and-enzyme-activated-prodrug-therapy
#5
JOURNAL ARTICLE
Li Xu, Xiaohong Liu, Yinping Li, Zhenhao Yin, Lan Jin, Lili Lu, Jingyao Qu, Min Xiao
The synthesis of rhamnosylated compounds has gained great importance since these compounds have potential therapeutic applications. The enzymatic approaches for glycosylation of bioactive molecules have been well developed; however, the enzymatic rhamnosylation has been largely hindered by lacking of the glycosyl donor for rhamnosyltransferases. Here, we employed an α-L-rhamnosidase from Alternaria sp. L1 (RhaL1) to perform one-step rhamnosylation of anticancer drugs, including 2'-deoxy-5-fluorouridine (FUDR), cytosine arabinoside (Ara C), and hydroxyurea (Hydrea)...
October 2019: Applied Microbiology and Biotechnology
https://read.qxmd.com/read/30217687/-cytopenia-under-topical-imiquimod-in-two-patients-treated-with-oral-hydroxyurea
#6
JOURNAL ARTICLE
C Joachim, V Gras-Champel, J-P Marolleau, G Chaby, M Dairi, E Carmi
BACKGROUND: Aldara® is a topical immunomodulatory treatment. The risks of systemic passage are minimal. There have been rare reports of systemic adverse effects. PATIENTS AND METHODS: Case 1. Five sachets weekly of imiquimod were prescribed for Bowen's disease on the forearm in a patient known to have essential thrombocytosis under Hydrea® . His CBC was normal (6000 leukocytes/mm3 , 2200 PMN/mm, 230,000 platelets/mm3 ). Imiquimod was given in 15 sachets weekly...
September 11, 2018: Annales de Dermatologie et de Vénéréologie
https://read.qxmd.com/read/26844848/in-vitro-in-vivo-evaluation-of-radiolabeled-99m-tc-co-3-hydroxyurea-and-fluorescein-isothiocyanate-hydroxyurea
#7
JOURNAL ARTICLE
Baris Yilmaz, Serap Teksoz, Ayfer Yurt Kilcar, Eser Ucar, Cigdem Ichedef, Emin Ilker Medine, Kadir Ari
The aim of current study is to examine hydroxyurea (HU), which is an antineoplastic drug used for the treatment of leukemia, sickle-cell disease, HIV, psoriasis, thrombocythemia, and various neoplastic diseases in two aspects. The active ingredient hydroxyurea was obtained by purification of the capsule form drug, commercially named as HYDREA. Then, [(99m)Tc(CO)3](+)core radiolabeling with HU was performed as first aspect. Quality control studies of (99m)Tc(CO)3-HU complex were performed by thin-layer radiochromatography and high-performance liquid radiochromatography methods...
February 2016: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/24618089/the-analgesic-effect-of-electrostimulation-woundel%C3%A2-in-the-treatment-of-leg-ulcers
#8
JOURNAL ARTICLE
Pauline Leloup, Pascal Toussaint, Jean-Paul Lembelembe, Philippe Célérier, Hervé Maillard
This study aims to demonstrate the analgesic efficacy of electrostimulation (ES), a recognised treatment for leg ulcers. Patients treated by ES for leg ulcers between 2011 and 2013 were included in the study. The pain score obtained with the numerical rating scale (NRS) was reported before the start of the ES (D0), after 3 days (D3) and 1 week following treatment initialisation. The analgesic treatments (AT) were reported at each assessment. Seventy-three patients were included (mean age 75·19 years): 31 venous leg ulcers, 21 mixed venous leg ulcers, 2 arterial ulcers, 17 hypertensive ischaemic ulcers, 1 Hydrea(®)-induced ulcer and an amputation stump ulcer...
December 2015: International Wound Journal
https://read.qxmd.com/read/24399021/refractory-anemia-with-ringed-sideroblasts-and-thrombocytosis-without-jak2-v617f-mutation-report-of-three-cases
#9
JOURNAL ARTICLE
Aurelia Tatic, Mariana Vasilică, Adriana Coliţă, Didona Vasilache, Camelia Dobrea, Cerasela Jardan, Amelia Maria Găman, Ana Manuela Crişan, D Coliţă, D Coriu
In the WHO classification, there is a provisional entity called Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U). Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) was included in this category. Recently published studies report a small percentage of patients with RARS-T. Sixty percent of these have JAK2 V617F mutation, which can suggest the coexistence of two pathological conditions (MDS and MPN). In this paper, we analyzed three patients diagnosed with RARS-T in the Department of Hematology, "Fundeni" Clinical Institute, Bucharest, Romania, during the period 2005-2011...
2013: Romanian Journal of Morphology and Embryology
https://read.qxmd.com/read/22973866/do-we-need-authorized-orphan-drugs-when-compounded-medications-are-available
#10
JOURNAL ARTICLE
M Dooms, H Pincé, S Simoens
WHAT IS KNOWN AND OBJECTIVE: Orphan drugs are used to diagnose, prevent or treat a rare disease. This Commentary aims to present a number of case studies questioning the need for designating compounded medications with a long history of effective use, which is well-supported by published clinical evidence. COMMENT: Prior to the market introduction of orphan drugs, medication compounding was done in our hospital pharmacy for several rare diseases. Examples include amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (Firdapse(®)), ibuprofen for the treatment of neonatal patent ductus arteriosus (Pedea(®)) and zinc acetate for the treatment of Wilson's disease (Wilzin(®))...
February 2013: Journal of Clinical Pharmacy and Therapeutics
https://read.qxmd.com/read/22665797/discovery-of-antimicrobial-ribonucleotide-reductase-inhibitors-by-screening-in-microwell-format
#11
JOURNAL ARTICLE
Fredrik Tholander, Britt-Marie Sjöberg
Ribonucleotide reductase (RNR) catalyzes reduction of the four different ribonucleotides to their corresponding deoxyribonucleotides and is the rate-limiting enzyme in DNA synthesis. RNR is a well-established target for the antiproliferative drugs Gemzar and Hydrea, for antisense therapy, and in combination chemotherapies. Surprisingly, few novel drugs that target RNR have emerged, partly because RNR activity assays are laboratory-intense and exclude high-throughput methodologies. Here, we present a previously undescribed PCR-based assay for RNR activity measurements in microplate format...
June 19, 2012: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/20860662/strategies-to-improve-efficacy-and-safety-of-a-novel-class-of-antiviral-hyper-activation-limiting-therapeutic-agents-the-vs411-model-in-corrected-hiv-aids
#12
RANDOMIZED CONTROLLED TRIAL
D De Forni, M R Stevens, F Lori
BACKGROUND AND PURPOSE: Antiviral hyper-activation-limiting therapeutic agents (AV-HALTs) are a novel experimental drug class designed to both decrease viral replication and down-regulate excessive immune system activation for the treatment of chronic infections, including human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome. VS411, a first-in-class AV-HALT, is a single-dosage form combining didanosine (ddI, 400 mg), an antiviral (AV), and hydroxyurea (HU, 600 mg), a cytostatic agent, designed to provide a slow release of ddI to reduce its maximal plasma concentration (C(max)) to potentially reduce toxicity while maintaining total daily exposure (AUC) and the AV activity...
October 2010: British Journal of Pharmacology
https://read.qxmd.com/read/20230722/relationship-between-alcohol-drinking-and-aspartate-aminotransferase-alanine-aminotransferase-ast-alt-ratio-mean-corpuscular-volume-mcv-gamma-glutamyl-transpeptidase-ggt-and-apolipoprotein-a1-and-b-in-the-u-s-population
#13
JOURNAL ARTICLE
Suthat Liangpunsakul, Rong Qi, David W Crabb, Frank Witzmann
OBJECTIVE: The misuse of alcohol, even at levels just above two drinks per day, is a public health problem, but identifying patients with this potentially unhealthy drinking is hindered by the lack of tests. Several blood tests, such as those testing for gamma-glutamyl transpeptidase (GGT) or mean corpuscular volume (MCV), are among the commonly used markers to identify very heavy drinking, but combinations of these markers have rarely been tested in lighter drinkers. We examined the relationship between alcohol drinking and the levels of these markers in a national population-based study composed primarily of lighter drinkers...
March 2010: Journal of Studies on Alcohol and Drugs
https://read.qxmd.com/read/18517111/beta-thalassaemia-major-bone-marrow-versus-peripheral-blood-stem-cell-transplantation
#14
COMPARATIVE STUDY
Muhammad Irfan, Khalil Hashmi, Salman Adil, Tahir Shamsi, Tasneem Farzana, Saquib Ansari, Vinodh Panjwani, Pervaiz Ahmed, Badshah Khan
OBJECTIVE: To compare PBSCT with BMT in Thalassaemia patients in terms of rejection, non-rejection mortality, disease free survival and overall survival. METHODS: Fifty six patients were transplanted from September 2000 - July 2005. Twenty nine underwent BMT and 27 received PBSCT. Most patients were intensely transfused to keep minimum haemoglobin of 12 gm/dl and received desferioxamine, 24 hours infusion, before transplantation. Pesaro class I (n-20) and class II (n-20) received conditioning with standard Bu/Cy...
March 2008: JPMA. the Journal of the Pakistan Medical Association
https://read.qxmd.com/read/17477059/-influence-of-antitumor-preparations-on-the-concentration-of-free-radicals-in-cells-of-fusarium-bulbigenum-var-blasticola-fungus-during-primary-and-tumour-like-secondary-growth
#15
JOURNAL ARTICLE
Iu A Riabikin, E T Nikitina, A S Balgimbatva, O V Zashkvara, S Sh Shakiev
The fungus Fusarium bulbigenum var. blasticola in which secondary tumor-like formations appear under certain conditions in aging was used as a new test system to examine the action of antitumor preparations. Free radicals in the primary mycelium and tumor-like formations without introduction of preparations (control samples) and after the introduction of preparation into the cultivation medium of the fungus have been studied by EPR spectroscopy. The EPR spectra of the fungus represent single, somewhat asymmetrical lines with a width of deltaH = 0...
March 2007: Biofizika
https://read.qxmd.com/read/17053739/-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-following-imatinib-therapy
#16
JOURNAL ARTICLE
P Le Nouail, V Viseux, G Chaby, A Billet, J P Denoeux, C Lok
BACKGROUND: Imatinib (Gleevec) is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. We describe a case of drug reaction with eosinophilia and systemic symptoms (DRESS) after institution of treatment with imatinib. PATIENT AND METHODS: A 78-year-old woman was treated with low-dose imatinib for chronic myeloid leukemia since November 2003. A macular and pruritic eruption appeared on the patient's trunk after 7 weeks of treatment and gradually worsened...
August 2006: Annales de Dermatologie et de Vénéréologie
https://read.qxmd.com/read/11766345/-treatment-plan-and-informed-consent
#17
REVIEW
K Ozawa
Since STI571, a BCR-ABL tyrosine kinase inhibitor, has made a great therapeutic advance in the management of CML, we have to reconsider the treatment protocol for chronic phase CML. Interferon-alpha (IFN-alpha) will be replaced with STI571 therapy. However, some patients are reported to become refractory to STI571, and it is unclear whether STI571 therapy alone may be sufficient to induce long-term survival in CML. There are also important progress in the field of allogeneic hematopoietic stem cell transplantation (SCT); i...
December 2001: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://read.qxmd.com/read/11365897/advantages-of-hiv-treatment-with-hydrea-hydroxyurea
#18
B Baker
No abstract text is available yet for this article.
September 1998: Positively Aware: the Monthly Journal of the Test Positive Aware Network
https://read.qxmd.com/read/11271979/the-biology-and-treatment-of-chronic-myelogenous-leukemia
#19
REVIEW
Claudio G Brunstein, Philip B Mcglave
Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to CML have been developed that increase the options available to newly diagnosed patients, and that can cure or prolong survival in this formerly incurable disease. Newly diagnosed patients presenting with extreme leukocytosis or thrombocytosis may benefit from immediate therapy with hydroxyurea (Hydrea) and pheresis...
January 2001: Oncology (Williston Park, NY)
https://read.qxmd.com/read/9887281/leukocyte-function-in-chronic-myeloproliferative-disorders
#20
COMPARATIVE STUDY
B Wolach, R Gavrieli, Y Manor, M Lishner
The myeloproliferative disorders (MPD) are clonal diseases that originate from a transformed stem cell and involve all myeloid lineage. The affected cells have both proliferative and functional impairment. Therefore, we evaluated and compared neutrophil function in 31 patients with polycythemia vera (PV), idiopathic myelofibrosis (MF), chronic myeloid leukemia (CML), and essential thrombocytosis (ET). Neutrophil chemotaxis, random migration, bactericidal activity and superoxide anion release in these patients were simultaneously compared to those of 31 healthy controls...
December 1998: Blood Cells, Molecules & Diseases
keyword
keyword
100192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.